These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Physio-chemical considerations on a chromatic phenomenon produced by a mixture of rifamycin S and SV in the free acid state]. Curci G; Sarluca F G Ital Chemioter; 1966; 13(1):27-31. PubMed ID: 5994447 [No Abstract] [Full Text] [Related]
5. [The composition of rifamycin B and related rifamycins]. Oppolzer W; Prelog V; Sensi P Experientia; 1964 Jun; 20(6):336-9. PubMed ID: 5855864 [No Abstract] [Full Text] [Related]
6. The x-ray analysis of the structure of rifamycin Y. Brufani M; Fedeli W; Giacomello G; Vaciago A Experientia; 1967 Jul; 23(7):508-12. PubMed ID: 6057726 [No Abstract] [Full Text] [Related]
7. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Barditch-Crovo P; Trapnell CB; Ette E; Zacur HA; Coresh J; Rocco LE; Hendrix CW; Flexner C Clin Pharmacol Ther; 1999 Apr; 65(4):428-38. PubMed ID: 10223781 [TBL] [Abstract][Full Text] [Related]
9. Chemotherapeutic activity of new derivatives of rifamycin. Kradolfer F; Neipp L; Sackmann W Antimicrob Agents Chemother (Bethesda); 1966; 6():359-64. PubMed ID: 5985258 [No Abstract] [Full Text] [Related]
10. Pharmacokinetic and metabolic studies with labeled rifamycin antibiotics. Keberle H; Meyer-Brunot H; Schmid K Antimicrob Agents Chemother (Bethesda); 1966; 6():365-70. PubMed ID: 5985259 [No Abstract] [Full Text] [Related]
11. New drugs for tuberculosis. Grassi C; Peona V Eur Respir J Suppl; 1995 Sep; 20():714s-718s. PubMed ID: 8590571 [TBL] [Abstract][Full Text] [Related]
12. Dissolution testing. Aspesi F Bull Int Union Tuberc Lung Dis; 1989 Mar; 64(1):37-8; 40-2 discussion. PubMed ID: 2743049 [No Abstract] [Full Text] [Related]
13. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Li J; Munsiff SS; Driver CR; Sackoff J Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767 [TBL] [Abstract][Full Text] [Related]
14. New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases. Combrink KD; Denton DA; Harran S; Ma Z; Chapo K; Yan D; Bonventre E; Roche ED; Doyle TB; Robertson GT; Lynch AS Bioorg Med Chem Lett; 2007 Jan; 17(2):522-6. PubMed ID: 17070048 [TBL] [Abstract][Full Text] [Related]
15. New rifamycins. II. Synthesis and biological activity of oximes, hydrazones, and semicarbazones of 3-N-(piperidin-4-one)rifamycin S. Marsili L; Franceschi G; Galliani C; Sanfilippo A; Vigevani A Farmaco Sci; 1982 Dec; 37(12):781-6. PubMed ID: 7152013 [No Abstract] [Full Text] [Related]
16. In vitro activity of a new rifamycin derivative against Mycobacterium leprae. Dhople AM; Dimova V Arzneimittelforschung; 1996 Feb; 46(2):210-2. PubMed ID: 8720317 [TBL] [Abstract][Full Text] [Related]
17. Identification of rifamycin B as nancimycin. Schwarz JS J Antibiot (Tokyo); 1967 Jul; 20(4):238. PubMed ID: 6072901 [No Abstract] [Full Text] [Related]
18. New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis. Barluenga J; Aznar F; García AB; Cabal MP; Palacios JJ; Menéndez MA Bioorg Med Chem Lett; 2006 Nov; 16(22):5717-22. PubMed ID: 16987658 [TBL] [Abstract][Full Text] [Related]